Primary Cutaneous MZL with Amyloid Deposition, Initially Misdiagnosed as Amyloidosis Mimics Primary Dural MZL upon Dural Dissemination

Miaoxia He, Lili Wu, Minghua Zhu, Chenguang Bai, Shimin Zhang, Jianjun Wang

Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Molecular Diagnopsis Laboratories, Armed Forces Institute of Pathology, Washington DC, USA.

DOI: 10.4236/ojpathology.2013.31004                

Abstract

Primary cutaneous marginal zone B-cell lymphoma (MZL) is considered a cutaneous counterpart of extranodal MZL of mucosa-associated lymphoid tissue and an indolent lymphoma. Amyloid deposition in this tumor is very rare. We report here a case of primary cutaneous MZL with massive amyloid deposition. The tumor disseminated to the dura and mimicked primary dural MZL. The patient had a four year history of the recurrence cutaneous lesions with a misdiagnosis of amyloidosis. The correct diagnosis was made after the metastatic dural lesion was confirmed by radiology, pathology and molecular biology approaches. It is of crucial importance for differential diagnosis to avoid misdiagnosis and the patients are indeed required long-term regular examinations and treatment because of the possibility of recurrence or dissemination.

Keywords

Skin; Dura; Amyloid Deposition; MZL; Dissemination

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, et al., “World Health Organization Classification of Tumour, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer,” IARC Press, Lyon, 2008.
[2]	N. J. Senff, E. M. Noordijk, Y. H. Kim, M. Bagot, et al., “European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma Consensus Recommendations for the Management of Cutaneous B-Cell Lymphomas,” Blood, Vol. 112, No. 5, 2008, pp. 1600-1609. doi:10.1182/blood-2008-04-152850
[3]	J. H. Cho-Vega, F. Vega, G. Rassidakis and L. J. Medeiros, “Primary Cutaneous Marginal Zone B-Cell Lymphoma,” American Journal of Clinical Pathology, Vol. 125, Suppl. 1, 2006, pp. S38-S49.
[4]	A. L. Breton, N. Poulalhon, B. Balme, L. Thomas, et al., “Primary Cutaneous Marginal Zone Lymphoma as a Complication of Radiation Therapy: Case Report and Review,” Dermatology Online Journal, Vol. 16, No. 12, 2010, p. 6.
[5]	S. Pittaluga, L. Bijnens, I. Teodorovic, A. Hagenbeek, et al., “Clinical Analysis of 670 Cases in Two Trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped According to the Revised European-American Classification of Lymphoid Neoplasms: A Comparison with the Working Formulation,” Blood, Vol. 87, No. 10, 1996, pp. 4358-4367.
[6]	J. D. Gillmore, P. N. Hawkins and M. B. Pepys, “Amyloidosis: A Review of Recent Diagnostic and Therapeutic Developments,” British Journal of Haematology, Vol. 99, No. 2, 1997, pp. 245-256. doi:10.1046/j.1365-2141.1997.303194.x
[7]	G. Goteri, R. Ranaldi, S. A. Pileri and I. Bearzi, “Localized Amyloidosis and Gastrointestinal Lymphoma: A Rare Association,” Histopathology, Vol. 32, No. 4, 1998, pp. 348-355. doi:10.1046/j.1365-2559.1998.00409.x
[8]	M. Kojima, S. Sugihara, M. Iijima, T. Ono, et al., “Marginal Zone B-Cell Lymphoma of Minor Salivary Gland Representing Tumor-Forming Amyloidosis of the Oral Cavity. A Case Report,” Journal of Oral Pathology & Medicine, Vol. 35, No. 5, 2006, pp. 314-316. doi:10.1111/j.1600-0714.2006.00408.x
[9]	T. Satani, T. Yokose, T. Kaburagi, Y. Asato, et al., “Amemiya. Amyloid Deposition in Primary Pulmonary Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid,” Pathology International, Vol. 57, No. 11, 2007, pp. 746-750. doi:10.1111/j.1440-1827.2007.02164.x
[10]	D. Gupta, V. Shidham, V. Zemba-Palko and A. Keshgegian, “Primary Bilateral Mucosa-Associated Lymphoid Tissue Lymphoma of the Breast with Atypical Ductal Hyperplasia and Localized Amyloidosis. A Case Report and Review of the Literature,” Archives of Pathology & Laboratory Medicine, Vol. 124. No. 8, 2000, pp. 1233-1236.
[11]	P. H. Tu, C. Giannini, A. R. Judkins, J. M. Schwalb, et al., “A. Perry. Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma,” Journal of Clinical Oncology, Vol. 23, No. 24, 2005, pp. 5718-5727. doi:10.1200/JCO.2005.17.624
[12]	A. C. George,M. Ozsahin, R. Janzer, S. Agassis, et al., “Primary Intracranial Dural Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type: Report of One Case and Review of the Literature,” Bull Cancer, Vol. 92, No. 7, 2005, pp. E51-E56.
[13]	F. P. Saggioro, B. O. Colli, A. N. Paixao-Becker. G. G. de Rezende, et al., “Primary Low-Grade MALT Lymphoma of the Dura,” Histopathology, Vol. 49, No. 3, 2006. pp. 323-326.
[14]	S. Bayraktar, A. Stefanovic, N. Montague, J. Davis, et al., “Central Nervous System Manifestations of Marginal Zone B-Cell Lymphoma,” Annals of Hematology, Vol. 89, No. 10, 2010, pp. 1003-1009.
[15]	C. Thieblemont, F. Berger, C. Dumontet, I. Moullet, et al., “Mucosa-Associated Lymphoid Tissue Lymphoma Is a Disseminated Disease in One Third of 158 Patients Analyzed,” Blood, Vol. 95, No. 3, 2000, pp. 802-806.
[16]	J. P. de Boer, R. F. Hiddink, M. Raderer, N. Antonini, et al., “Dissemination Patterns in Non-Gastric MALT Lymphoma,” Haematologica, Vol. 93, No. 2, 2008, pp. 201-206. doi:10.3324/haematol.11835
[17]	C. Suh, J. Huh and J. L. Roh, “Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Arising in the Extracranial Head and Neck Region: A High Rate of Dissemination and Disease Recurrence,” Oral Oncology, Vol. 44, No. 10, 2008, pp. 949-955. doi:10.1016/j.oraloncology.2007.11.011
[18]	A. Topalkara, Y. Ben-Arie-Weintrob, J. A. Ferry and C. S. Foster, “Conjunctival Marginal Zone B-Cell Lymphoma (MALT Lymphoma) with Amyloid and Relapse in the Stomach,” Ocular Immunology and Inflammation, Vol. 15, No. 4, 2007, pp. 347-350. doi:10.1080/09273940701375410
[19]	M. Raderer, F. Vorbeck, M. Formanek, C. Osterreicher, et al., “Importance of Extensive Staging in Patients with Mucosa-Associated Lymphoid Tissue (MALT)-Type Lymphoma,” British Journal of Cancer, Vol. 83, No. 4, 2000, pp. 454-457. doi:10.1054/bjoc.2000.1308
[20]	M. Raderer, B. Streubel, S. Woehrer, A. Puespoek, et al., “High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-Up,” Clinical Cancer Research, Vol. 11, No. 9, 2005, pp. 3349-3352. doi:10.1158/1078-0432.CCR-04-2282